Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial
European Respiratory Journal · 2025-04 · 65 (4) · 2402249
DOI: 10.1183/13993003.02249-2024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 28.03.2025. Verfasst von Guadalupe Bermudo-Peloche und 37 weiteren Autor:innen. Beteiligte Einrichtung: Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Pulmonary Fibrosis, Pyridones. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CERCA Program, Instituto de Salud Carlos III, Roche.
Abstract (Originalsprache)
Background
Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated.
Methods
This was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL), exercise capacity and drug safety profile.
Results
From 119 eligible patients, 113 were randomised and 103 were analysed (pirfenidone n=69 and placebo n=34). Most patients were male (73.5%) and were receiving low-dose prednisone; mean age was 63.7 years and mean body mass index was 29 kg·m −2 . The percentage of patients that improved was similar in the pirfenidone and placebo groups (79.7% versus 82.3%, respectively). The mean predicted FVC increased by 12.74±20.6% with pirfenidone and 4.35±22.3% with placebo (p=0.071), and the HRCT (%) fibrotic score decreased by 5.44±3.69% with pirfenidone and 2.57±2.59% with placebo (p=0.52). Clinically meaningful improvement in HRQoL was not statistically different (55.2% in the pirfenidone group and 39.4% in the placebo group). Exercise capacity, adverse events and hospitalisations were similar between groups. No deaths were reported.
Conclusions
The overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
- National Network of Research in Respiratory Diseases (CIBERES), Barcelona, Spain.
- Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- Interstitial Lung Disease Unit, Radiology Department, Bellvitge University Hospital, University of Barcelona - L'Hospitalet de Llobregat, Barcelona, Spain.
- Interstitial Lung Disease Unit, Respiratory Department, Hospital La Princesa, Madrid, Spain.
- Respiratory Department, Hospital Puerta Hierro, Majadahonda, Spain.
ORCID-Profile: Vanesa Vicens-Zygmunt, Jaume Bordas-Martinez, Claudia Valenzuela, Juan Rigual Bobillo, Paloma Millán-Billi, Diego Castillo
Förderung
- CERCA Program
- Instituto de Salud Carlos III
- Roche
Zitieren
APA
Bermudo-Peloche, G., Del Rio, B., Vicens-Zygmunt, V., Bordas-Martinez, J., Hernández, M., Valenzuela, C., Laporta, R., Rigual Bobillo, J., Portillo, K., Millán-Billi, P., Balcells, E., Badenes-Bonet, D., Bolivar, S., Rodríguez-Portal, J. A., López Ramirez, C., Tomás, L., Fernández de Roitegi, K., Sellarés, J., Castillo, D., …, & Molina-Molina, M. (2025). Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. European Respiratory Journal, 65(4), 2402249. https://doi.org/10.1183/13993003.02249-2024
Vancouver
Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V, Bordas-Martinez J, Hernández M, Valenzuela C, et al. Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. European Respiratory Journal. 2025;65(4):2402249. doi:10.1183/13993003.02249-2024
BibTeX
@article{BermudoPeloche2025,
author = {Bermudo-Peloche, Guadalupe and Del Rio, Belén and Vicens-Zygmunt, Vanesa and Bordas-Martinez, Jaume and Hernández, Marta and Valenzuela, Claudia and Laporta, Rosalía and Rigual Bobillo, Juan and Portillo, Karina and Millán-Billi, Paloma and Balcells, Eva and Badenes-Bonet, Diana and Bolivar, Santi and Rodríguez-Portal, José-Antonio and López Ramirez, Cecilia and Tomás, Laura and Fernández de Roitegi, Koral and Sellarés, Jacobo and Castillo, Diego and González, Jessica and Barril, Silvia and Gutiérrez-Rodríguez, Yasmina and Caballero, Paloma and Alarcon, Javier and Peñafiel, Judith and Sanz-Santos, Jose and Blavia, Rosana and Caupena, Cristina and Segovia, Pilar and Santos-Pérez, Salud and Ferrer-Artola, Anna and Badia, Maria B and Hereu, Pilar and Fuentes, Mireya and Montes-Worboys, Ana and Franquet, Tomás and Luburich, Patricio and Molina-Molina, María},
title = {Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial},
journal = {European Respiratory Journal},
year = {2025},
volume = {65},
number = {4},
pages = {2402249},
doi = {10.1183/13993003.02249-2024}
}
EUVIMED